DXCMDEXCOM INC
Surgical & Medical Instruments & Apparatus
- Revenue
- $4.7B
- 16% YoY
- Operating margin
- 19.6%
- 31% YoY
- EBITDA
- $1.2B
- 42% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -0.8×
- −$959M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear172% of net incomeCash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear35% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B | 16% |
| Operating income | $266M | $391M | $598M | $600M | $912M | 52% |
| Net income | $217M | $341M | $542M | $576M | $836M | 45% |
| Operating cash flow | $443M | $670M | $749M | $990M | $1.4B | 46% |
| Capex | $389M | $365M | $237M | $359M | $364M | 1.3% |
| Stock-based comp | $113M | $127M | $151M | $170M | $160M | 6.3% |
| Buybacks | $0 | $558M | $689M | $750M | $500M | 33% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 7
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 72 | 79 |
| FY2024 | — | — | 84 | 79 |
| FY2023 | — | — | 134 | 75 |
| FY2022 | — | — | 123 | 79 |
| FY2021 | — | — | 145 | 104 |